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Position statement
A B S T R A C T
Insomnia, vasomotor symptoms (VMS) and depression often co-occur after the menopause, with consequent
health problems and reductions in quality of life. The aim of this position statement is to provide evidence-based
advice on the management of postmenopausal sleep disorders derived from a systematic review of the literature.
The latter yielded results on VMS, insomnia, circadian rhythm disorders, obstructive sleep apnea (OSA) and
restless leg syndrome (RLS). Overall, the studies show that menopausal hormone therapy (MHT) improves VMS,
insomnia, and mood.
Several antidepressants can improve insomnia, either on their own or in association with MHT; these include
selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and
mirtazapine. Long-term benefits for postmenopausal insomnia may also be achieved with non-drug strategies
such as cognitive behavioral therapy (CBT) and aerobic exercise. Continuous positive airway pressure (CPAP)
and mandibular advancement devices (MADs) both reduce blood pressure and cortisol levels in postmenopausal
women suffering from OSA. However, the data regarding MHT on postmenopausal restless legs syndrome are
conflicting.
1. Introduction
In women, aging and transition through menopause are accom-
panied by an increased prevalence of sleep disturbances. The Study of
Women's Health Across the Nation (SWAN) [1] found that progression
through the menopausal transition was associated with increasing self-
reported sleep disturbances.
Sleep disturbances during the menopause include difficulty in sleep
initiation or continuation, a higher frequency of night awakenings and
poor-quality, non-restorative sleep. Sleep quality is worse in post-
menopausal than in premenopausal women, with respect to both pro-
longed sleep latency (SL) and increased nocturnal time awake.
Other primary sleep disorders appear to increase during the peri-
and postmenopausal years, including obstructive sleep apnea (OSA),
with a prevalence of 45.2% for mild to moderate OSA and 10.1% for
severe OSA (AHI > 30) [2], as well as sleep-related movement
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disorders. Periodic leg movement disorders (PLMD) and restless legs
syndrome (RLS) increase both in prevalence and in severity in the
postmenopausal years [3].
Sleep disturbances during the menopause have been ascribed to
several factors: physiological changes of aging, menopausal-related
symptoms, stress, mood symptoms (e.g. depression and anxiety), and
chronic health issues. Whether sleep problems during the menopausal
years are the result of sleep being interrupted by vasomotor symptoms
(VMS) or whether they are separate entities is still unclear.
Despite the importance of recognizing and treating sleep disorders
in midlife women, relatively few studies have examined the effect of
hormonal and non-hormonal treatments on sleep disorders and they
have produced inconsistent findings. There is wide heterogeneity in the
studies with respect to the various formulations used, treatment dura-
tion, the timing of treatment in relation to the menopause transition,
and the inclusion and exclusion criteria of the clinical trials.
Furthermore, there are no specific treatments for postmenopausal
narcolepsy and other primary hypersomnias. The same is true for most
parasomnias, with the exception of secondary enuresis and rapid eye
movement (REM) behavior disorder (RBD), whose prevalence increases
with age in both sexes, but again no therapy specifically targets post-
menopausal women.
Finally, data concerning therapy are far from being uniform in re-
lation to sleep-related movement disorders, such as PLMD and RLS, and
nor do they cast any light on symptom aggravation [3].
This position statement and guideline on the treatment of post-
menopausal sleep disorders by the Italian Association of Sleep Medicine
(AIMS) was undertaken in 2017 by the Gender Sleep Medicine
Committee, which acted as a task force. The position statement results
from a systematic literature review (Table 1, Fig. 1).
2. Methods
All studies specifically addressing the treatment of postmenopausal
sleep disorders from January 2000 until December 2018 were included
in the review. Published studies were identified from the National
Library of Medicine (Medline Database, Google Scholar and Scopus) by
means of a search strategy using a combination of MESH terms and text
combining the concepts of different sleep disorders and menopause.
Postmenopause was defined as starting one year after the last sponta-
neous menstrual cycle. Included studies had to address the therapy of
postmenopausal sleep disorders according to one of the following
methodologies: case-series, case controls, cross-sectional studies, cohort
studies, clinical trials (CTs), controlled clinical trials (CCTs), rando-
mized controlled trials (RCTs) and systematic reviews (Fig. 1). Exclu-
sion criteria included: language other than English, unavailable full-
length texts, dissertations, animal studies, correspondence, health let-
ters, and case reports. After applying these criteria, 53 studies were
taken into consideration. Among these, a maximum of 7 studies for
each sleep disorder met the criteria. Table 1 summarizes all 23 RCTs
discussed in the subsections below.
3. Sleep disorders in the menopause
In the following sections, we discuss the treatment of vasomotor
symptoms, insomnia, circadian rhythm disorders, obstructive sleep
apnea, and restless legs syndrome. Narcolepsy/ hypersomnia is not
included due to the absence of studies in postmenopausal women.
3.1. Sleep disorders, vasomotor symptoms, menopausal hormone therapy
and non-hormonal options
Estrogen-based therapy is known to be beneficial in treating me-
nopause-related symptoms and improving the quality of life of post-
menopausal women and is recommended in national and international
guidelines [see for example 4,5]. Hormonal and non-hormonal
pharmacological options will be discussed as well as non-drug thera-
pies, as treatment needs to be individualized to a woman’s needs and
preferences [4,[5].
Estrogen therapy with or without progesterone/ progestogen in
non-hysterectomized women is very effective in treating VMS, thus
indirectly improving sleep quality through a domino effect. By im-
proving VMS, menopausal hormone therapy (MHT) improves sleep
quality by decreasing the frequency of nighttime wakening, as shown in
a study of women with severe hot flushes with objectively measured
skin temperature and resistance and waking episodes [6]. A systematic
review of MHT for the treatment of chronic insomnia during the me-
nopause was published by Attarian et al. in 2015 [7]. They identified
and reviewed 23 articles: 14 showed significant and continuous im-
provement in subjective sleep and VMS with low doses of estrogen,
whereas the other 9 found no significant change in sleep parameters. In
the same year Tansupswatdikul et al. [8] published a randomized,
double-blind, placebo-controlled trial, using a 50 μg transdermal es-
tradiol patch which could raise estradiol levels to within the range of
the follicular phase of the normal ovulatory cycle in postmenopausal
women with sleep disorders but without severe VMS and/or recognized
hot flushes during sleep. They found that estrogen therapy in insomniac
postmenopausal women without severe vasomotor symptoms and/or
recognized hot flushes during sleep did not improve sleep efficiency.
Therefore, there are differences in response to MHT between women
who have hot flushes during sleep and those who do not.
The tissue selective estrogen complex consisting of bazedoxifene/
conjugated estrogen (BZA/CE), has been evaluated in randomized,
double-blind, placebo-controlled trials [9,10]. An initial 12-week study
found that CE 0.45mg/BZA 20mg was associated with a significant
(p < 0.05) improvement of sleep latency scores, sleep disturbance and
sleep problem indices compared with placebo [9]. A subsequent one-
year randomized trial found that symptomatic postmenopausal women
treated with BZA/CE demonstrated significant improvements in sleep
and health-related quality of life, similar to women treated with CE/
medroxyprogesterone acetate (MPA) [10].
In addition, several studies show that MHT also alleviates depres-
sive symptoms, which may also affect sleep in perimenopausal and
postmenopausal women [11]. Thus, MHT is one of the recommended
treatments for menopausal insomnia. It improves both quality of sleep
and quality of life.
With regard to non-hormonal pharmacological treatments, some
antidepressants and mood stabilizers (such as venlafaxine and gaba-
pentin) can improve mood and VMS but may have negative effects on
symptoms of insomnia. Several trials have shown that venlafaxine, a
serotonin and norepinephrine reuptake inhibitor (SNRI), reduces VMS
in healthy postmenopausal women and breast cancer survivors [see
[12]]. Ensrud et al. [13] undertook a 3-arm double-blind randomized
trial of low-dose estradiol, low-dose venlafaxine and placebo to study
the effects on insomnia symptoms and sleep quality in peri- and post-
menopausal women with VMS. The Insomnia Severity Index (ISI) and
the Pittsburgh Sleep Quality Index (PSQI) were used to evaluate a pa-
tient’s perception of sleep and to analyze subjective elements of in-
somnia. Women treated with low-dose estradiol compared with parti-
cipants treated with placebo had a clinical improvement in subjective
sleep quality, and reductions in both ISI and PSQI scores. The authors
demonstrated a modest effect of treatment with venlafaxine in de-
creasing sleep disorders after 8 weeks of treatment. Low-dose venla-
faxine and low-dose estradiol in healthy menopausal women with VMS
were each more effective than placebo in reducing sleep disturbances
and improving sleep quality. Other antidepressants such as escitalo-
pram have also been found to improve hot flushes in randomized
controlled trials [see for example 14].
Amongst all the non-pharmacological approaches, cognitive beha-
vioral therapy (CBT) is the first-line treatment for chronic insomnia in
adults of any age, as detailed below. Other interventions include high-
intensity exercise, hypnosis, yoga, and massage therapy [7]. Studies
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evaluating the effects of aerobic training on menopausal symptoms and
sleep quality are scant. Mansikkamäki and colleagues [15] enrolled 176
sedentary women, aged 43–63 years with menopausal symptoms (daily
hot flushes), in a randomized controlled trial. Participants were ran-
domized to a six-month unsupervised aerobic training intervention
(50min 4 times per week) or a control group. The exercise program of
the intervention group consisted of aerobic training 4 times per week,
with 50min of exercise each time: women were to include at least two
sessions of walking or Nordic walking (walking with poles or sticks,
resembling cross-country skiing). At the end of study, women in the
intervention group reported better sleep quality and a reduction in
menopausal symptoms.
To conclude, hormonal and non-hormonal options have been found
to be beneficial and choice of therapy needs to be personalized to in-
dividual women’s comorbidities and preferences.
3.2. Insomnia
Management of insomnia during the menopausal transition con-
stitutes a priority for the improvement of well-being because of its
impact on daytime functioning, quality of life and health [16–19].
Treatments for insomnia during the menopause include sleep hygiene,
behavioral interventions, and drugs, mainly hypnotics.
Few pharmacological studies have focused on this specific popula-
tion, but these have shown positive results for hypnotics, anti-
depressants, melatonin, neuroleptics, and hormone therapy.
Non-benzodiazepine agonists of gamma-aminobutyric acid type A
(GABAA) were the only drugs in this class to have been evaluated in
randomized double-blind placebo studies. Zolpidem in 141 patients was
effective after 4 weeks [20], while two studies reported the efficacy of
eszopiclone at 3mg at 4 and 11 weeks, respectively, on 410 and 59
patients [21,22].
Ramelteon, an agonist of melatonin MT1 and MT2 receptors, has
been approved by the US FDA for the treatment of chronic insomnia. A
single open study of 20 menopausal women showed improvement in
sleep at a nocturnal dose of 8mg; that improvement became statisti-
cally significant at 4 weeks and even more pronounced at the sixth [23].
Few studies of antidepressants by menopausal women have con-
sidered sleep as an independent outcome measure. However, in a study
of 600 menopausal women with moderate / severe VMS, paroxetine
7.5 mg induced a significant reduction in associated awakenings and a
significant increase in total sleep time [24]. Of note, paroxetine is ap-
proved for the management of VMS by the FDA but not in Europe.
Among the other antidepressants, in a single study, mirtazapine 15mg
was administered to 11 non-depressed perimenopausal women with
chronic insomnia, for 4 weeks, followed by add-on prolonged-release
melatonin (PRM) 2mg for 4 weeks with mirtazapine suspension at 1–3
months. The significant improvement in scores on the Pittsburgh Sleep
Quality Index (PSQI) with mirtazapine persisted in the add-on phase
and with PRM monotherapy [25]. A prospective, randomized, 9-month,
placebo-controlled, double-blind study of citalopram and fluoxetine in
the treatment of postmenopausal symptoms in 150 women found an
improvement in insomnia only in the citalopram group [26].
Four studies have been conducted with escitalopram. An open-label
study showed similar effects of escitalopram (10–20mg) and estrogen-
based therapy in improving sleep and VMS in a group of 32 depressed
perimenopausal women [27]. A single-blind placebo-controlled study
demonstrated an improvement in mood, sleep patterns, VMS, and
overall quality of life with escitalopram 10–20mg in 25 women with
VMS [28]. Furthermore, in the previously mentioned randomized trial
of Freeman et al. [14], escitalopram improved insomnia symptoms and
subjective sleep quality in healthy menopausal women with HF.
Moreover, escitalopram 10–20mg/day was effective and well tolerated
for VMS, with improvement of subjective sleep quality and insomnia
Fig. 1. Selection of Relevant Studies Regarding the Treatment of Postmenopausal Sleep Disorders. PRISMA flow chart of selection process.
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symptoms at 8-week follow-up [29].
A study by Davari-Tanha comparing citalopram, venlafaxine, and
placebo with a sample of 60 patients concluded that while citalopram
and venlafaxine were equally more effective than placebo in reducing
sleep disturbance and severity of hot flushes, citalopram was more ef-
fective in reducing frequency of hot flushes than venlafaxine [30].
Furthermore, while venlafaxine seems to be slightly less effective than
low-dosage oral estradiol on VMS, the difference is small and of un-
certain clinical relevance [31].
The Health Network, involving 546 peri- and postmenopausal
women with ‘bothersome’ HF (between 12 or 13 episodes per week),
examined 6 types of interventions, using as outcome measures the
Insomnia Severity Index (ISI) and the Pittsburgh Sleep Quality Index
(PSQI) over 8 to 12 weeks of treatment [32]. Escitalopram 10–20mg/
day; yoga; aerobics exercises; 1.8 g / day omega-3 fatty acids; oral 17-
beta-estradiol 0.5mg/day; venlafaxine XR 75mg / day; and cognitive
behavioral therapy for insomnia (CBT-I) were evaluated. CBT-I proved
to be the most effective intervention, followed by venlafaxine and ex-
ercise, then escitalopram. CBT-I produced the largest reduction in ISI
score. The effects on ISI score were similar for exercise, at -2.1 points,
and venlafaxine, at -2.3 points, and with escitalopram, yoga, and es-
tradiol. The largest reduction in PSQI score from baseline was with
CBT-I, at -2.7 points (from -3.9 to -1.5), although the reductions in PSQI
score, from 1.2 to 1.6, were significantly better than those achieved by
escitalopram, exercise, yoga, estradiol, and venlafaxine. Omega-3 sup-
plements did not improve the symptoms of insomnia, mood disorders or
VMS [33], while in a single study of 100 postmenopausal women with
insomnia, valerian seemed to improve the quality of sleep [34].
Some experimental data in animals and in humans support the hy-
pothesis that menopausal estrogen deficiency could lead to a hyper-
activity of the orexinergic system and contribute to anxiety, insomnia,
and VMS [35]. It may therefore be hypothesized that orexin receptor
antagonists represent a new non-hormonal strategy for menopause
symptom management [36].
The initial cause of insomnia could be hormonal fluctuations and
VMS such as night sweats, but physiological awakenings, behavioral
conditioning, and maladaptive coping could act as perpetuating factors.
CBT-I targets these perpetuating behaviors and has been effective in the
treatment of chronic insomnia in randomized trials in adult and elderly
women [37].
Other non-pharmacological options such as acupuncture [38],
mindfulness, reflexology, exercise, and yoga have shown some positive
results in small groups, but these have yet to be confirmed in larger
studies. A short-term randomized trial has found a positive effect of
acupuncture on perimenopausal insomnia [38].
3.2.1. Cognitive behavioral therapy for insomnia (CBT-I)
According to recent European guidelines, it is recommended that
treatment of insomnia consists of psychological therapy, pharmacolo-
gical therapy, or a combination of both [39]. First-line treatment for
insomnia is considered to be cognitive behavioral therapy for insomnia
(CBT-I), which is multimodal and consists of a combination of cognitive
therapy, behavioral interventions, such as sleep restriction and stimulus
control, and educational interventions, such as sleep hygiene [40].
Three clinical studies on CBT-I have been undertaken and are de-
scribed below [Table 1].
Two studies belong to the Menopause Strategies Finding Lasting
Answers for Symptoms and Health research network (MsFLASH). The
trial conducted by McCurry et al. [40] was a single-site, randomized
controlled trial of a telephone CBT-I intervention versus telephone-de-
livered menopause education over 8 weeks in 104 perimenopausal
women with insomnia symptoms assessed with the Insomnia Severity
Index scale (ISI) and sleep diaries. The CBT-I and menopause education
interventions both consisted of six 20–30-minute telephone sessions
over eight weeks. The CBT-I protocol provided information about age/
menopause-related sleep changes and the rationale for a behavioral
approach, by re-scheduling sleep using sleep restriction and stimulus
control instructions, changing beliefs/attitudes about sleep, and ap-
plying sleep hygiene recommendations. The menopausal education
protocol included educational content and texts relevant to women's
health and quality of life. Sessions were designed to reduce uncertainty
about changes occurring during menopause and to help women identify
symptom self-management strategies with no practice or instruction in
CBT-I principles. This first randomized controlled trial showed that
brief, telephone-delivered CBT-I resulted in significant 8- and 24-week
improvements in self-reported insomnia symptoms, overall sleep
quality, sleep latency, wake time after sleep onset, and sleep efficiency
compared with the menopausal educational protocol. In addition, CBT-I
was able to reduce self-reported HF interference with sleep at 8 and 24
weeks compared with the menopausal educational protocol. The au-
thors hypothesized that the cognitive strategies taught during CBT-I
may reduce daytime dysfunction associated with sleep loss dependent
on VMS response.
A second study from MsFLASH [32] compared the results of several
randomized control trials studying the effects of different interventions
on insomnia and VMS. As previously seen, findings from these pooled
analyses suggested that telephone-delivered CBT-I was more effective
for reducing moderate to severe symptoms of insomnia in menopausal
women with HF than other commonly used pharmacological or lifestyle
modification options considered. In settings where CBT-I is not avail-
able, data have suggested that exercise and venlafaxine may produce
moderate improvements in both self-reported insomnia symptoms and
sleep quality ratings.
A recent controlled trial by Drake et al. [41] evaluated 150 post-
menopausal women with chronic insomnia according to DSM-5 criteria
and assessed with ISI and sleep diaries. Interventions were: sleep hy-
giene education, versus sleep restriction therapy, versus face-to-face
CBT-I. Blinded assessments were performed at baseline, post-treatment,
and 6 months after treatment. CBT-I and sleep restriction were more
effective in the treatment of insomnia than sleep hygiene education.
Although the responses to CBT-I and sleep restriction were similar, CBT-
I treatment exceeded sleep restriction in improving sleep maintenance,
a common problem following the menopausal transition.
Taken together, all three studies demonstrate the efficacy of CBT-I
in the treatment of menopausal insomnia, confirming it as a first-line
treatment for these symptoms. Despite this, data are not statistically
comparable.
3.3. Circadian rhythm disorders
Circadian misalignment has not been reported as a sleep disorder
within the menopausal transition. No studies have specifically ad-
dressed circadian rhythm disorder therapy in postmenopausal women.
The few studies undertaken have all found a decrease in melatonin
levels through aging and in particular after menopause [42–44]. Fur-
thermore, a study comparing healthy pre- and postmenopausal women
found that postmenopausal women had lower nighttime serum mela-
tonin concentrations than perimenopausal women. The duration of
melatonin secretion tended to be shorter in the postmenopause whereas
melatonin peak time did not differ. [45]. Furthermore, lower levels of
melatonin in postmenopausal women may correlate with depressive
symptoms [46]. Thus, melatonin therapy may have a favorable effect
on those and related symptoms, such as VMS [47].
3.4. Obstructive sleep apnea (OSA)
Obstructive sleep apnea (OSA) is a common disorder characterized
by loss of pharyngeal dilator muscle tone during sleep inducing re-
current upper airway collapse, leading to apnea and hypopnea. The
obstructive events are associated with intermittent hypoxia/ hy-
percapnia, intrathoracic pressure changes and sleep arousal. These in
turn unleash a series of cardiovascular and neurohumoral processes,
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including sympathetic nervous system hyperactivity, surges in heart
rate and blood pressure, myocardial wall stress, oxidative stress, sys-
temic inflammation, platelet aggregation, and impaired vascular en-
dothelial function, which all contribute to increased cardiovascular risk
[48]. It has therefore been suggested that OSA treatment could play a
pivotal role in cardiovascular prevention strategies. However, there is
little information on the effects of OSA treatment on cardiovascular
outcomes in women, in particular after the menopause.
Additionally, the studies of the cardiovascular effects of OSA
treatment in women have often produced conflicting results, probably
due to their methodological limitations: studies are different in meth-
odology, design, inclusion and exclusion criteria, outcomes, and treat-
ment approaches.
One of the few available studies on this topic is that undertaken by
Campos-Rodriguez et al. [49], who investigated the effect of CPAP on
blood pressure and glucose and lipid profiles in women with moderate
to severe OSA. This was a multicenter, open-label, randomized con-
trolled 12-week trial analyzing the effect of CPAP on blood pressure and
metabolic profile in 307 women aged 18–75 years, referred for suspi-
cion of OSA and diagnosed with moderate to severe OSA (apnea-hy-
popnea index (AHI)> 15 events/h). Women were randomized to CPAP
(n=151) or conservative treatment (n=156) for 12 weeks. Compared
with the control group, the CPAP group achieved a significantly greater
decrease in diastolic blood pressure, and an insignificantly greater de-
crease in systolic blood pressure and mean blood pressure. However,
CPAP therapy did not change any of the metabolic variables compared
with conservative treatment. The greatest changes in blood pressure
values were found in the group of women presenting excessive daytime
sleepiness with high systolic blood pressure or diastolic blood pressure
at baseline, and with severe OSA.
Positive effects of OSA treatment on blood pressure have been also
described in a study by Rietz and coworkers [50]. That study was a 4-
month, double-blind, randomized controlled trial to determine the ef-
fect of mandibular advancement device (MAD) therapy versus sham
devices on ambulatory nighttime and daytime blood pressure in women
and men with daytime sleepiness and snoring or mild to moderate sleep
apnea (apnea-hypopnea index< 30). The study included 27 women
and 58 men, aged 31–70 years. In women, MADs significantly lowered
mean nighttime systolic blood pressure and mean nighttime adjusted
diastolic blood pressure. In men, there were no significant differences in
blood pressure at night or during the daytime between the intervention
groups.
The effect of CPAP treatment on the hypothalamic–pituitary–a-
drenal axis was explored by Kritikou and coworkers [51] in a 2-month
placebo-controlled trial exploring the effect of CPAP versus sham CPAP
in 72 women and men. In both apneic men and women, OSA was as-
sociated with significantly higher 24-h cortisol levels compared with
controls, whereas CPAP lowered cortisol levels significantly, close to
those of controls.
On the other hand, Jennum et al. [52], who reported a registry
study with 10 years of follow-up, found that CPAP therapy was asso-
ciated with reduced all-cause mortality in middle-aged and elderly men,
but no significant effect was found in women. They showed that women
with OSA had lower mortality rates than men, irrespective of whether
or not they received CPAP treatment. CPAP had no significant effect in
20- to 39-year-olds, but the overall mortality in this age group was
small. Survival was increased by CPAP in 40- to 59-year-old and> 60-
year-old men, but no such effect was observed in women.
Finally, Anttalainen and coworkers [53] performed a placebo-con-
trolled, double-blind, parallel-group trial to assess the effects of pro-
gestogen medroxyprogesterone acetate [MPA] in stimulating breathing
and inducing sleep, and to compare MPA with CPAP. The study in-
volved 34 postmenopausal women whose sleep disordered breathing
had been treated with nasal CPAP for 6 months to 8 years prior to study
entry. The 6-week trial included measurements with CPAP at baseline,
after 14 days of placebo or MPA (60mg daily), and after a 3-week
washout. The study found that MPA induced a long-lasting stimulatory
effect on breathing without improving sleep quality or the apnea-hy-
popnea index.
To conclude, both CPAP and MADs appear to lower blood pressure
in women with OSA, with the greatest changes in those with severe
disease, daytime sleepiness, and hypertension. On the other hand, CPAP
adherence had no effect on mortality and MPA alone did not improve
apnea-hypopnea index, nor sleep quality.
3.5. Restless legs syndrome (RLS)
RLS is a sensorimotor neurological disorder characterized by an
urge to move the legs while resting, especially in the evening and at
night. The prevalence of RLS increases with age, from about 0.5% for
children to 5% for those older than70 years. In adults older than 40
years, RLS occurs about twice as often in women as in men [54].
Symptom severity increases after menopause [55,56].
Hachul et al. [57] reported worse RLS symptoms in the early com-
pared with late postmenopause, despite more sleep complaints in the
late postmenopausal group. However, no difference in poly-
somnography (PSG)-detected periodic leg movements (PLMs) was
found between the two groups. Furthermore, a positive correlation
between VMS and RLS symptoms was detected. In a later study [58],
the same authors reported more RLS subjective complaints in pre-
compared with postmenopausal women, whereas the PLMs index was
significantly higher in the postmenopausal group. A more recent study
[59] undertaken in 980 Iranian postmenopausal women found that the
prevalence of RLS was 16.02%. The risk was increased in women with
low socio-economic status, smokers and higher body mass index, and
reduced in MHT users.
A Swedish study reported increased prevalence of RLS among
women with VMS during the menopause transition, but not in MHT
users [60]. In a subsequent study [61], the same authors noted an as-
sociation between women with VMS and clinically significant periodic
limb movements (PLMs)/RLS, but not PLMs with arousal. The me-
chanisms underlying the association are unclear.
With regard to treatment Montplaisir et al. [62] report a positive
long-term effect of pramipexole (0.25-0.75 mg) on RLS severity in seven
patients, of whom 4 were women, mean age 55.4 years, evaluated after
1 month and after 7.8 months of therapy.
While MHT is an effective treatment for VMS [4,5], benefit has not
been found in RLS [63–67]. Indeed, MHT trials on RLS/PLMs mostly
suggest a negative or unmodified outcome, as reported by an extensive
review [3] that cites, among others, two particularly noteworthy stu-
dies. Of the latter, a randomized double-blind placebo-controlled
crossover study [63] conducted with 62 postmenopausal women re-
porting no RLS, but some PLMs (48%), showed that oral estradiol
(2.5 mg/day) or estradiol hemihydrate (50 μgs/24 h) patches did not
significantly affect PLMs compared with placebo (31% vs. 27%, re-
spectively).
Similarly, Montplaisir et al. [64], in a study of 21 postmenopausal
women with subjective complaints of poor nocturnal sleep but no his-
tory of RLS, found no significant difference in PLMs after six months of
MHT consisting of (1) estrogen (Premarin 0.625mg) and medrox-
yprogesterone acetate (Provera 5mg) (n=11) or (2) estrogen (Pre-
marin 0.625mg) and oral micronized progesterone (Prometrium
200mg).
A subsequent review paper [65] suggested that the situation is
complex in postmenopausal women with both VMS and RLS, especially
with cyclical progestogen addition. However, a case report described a
decrease in PLMs in a postmenopausal woman given transdermal es-
tradiol [66]. The same authors [67] subsequently undertook a rando-
mized placebo-controlled study of MHT on sleep in 33 postmenopausal
women. The women were initially given estrogen alone or placebo for
12 weeks. Then, while still taking estrogen or placebo, they all received
additional medroxyprogesterone acetate 5mg daily for another 12
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weeks. They found that estrogen plus medroxyprogesterone acetate was
more effective than estrogen alone in decreasing the prevalence of
PLMs and hot flashes.
Hence, in light of these studies, we agree with Manconi et al. [3]
that the available data with regard to MHT are insufficient to endorse
its use as a viable approach to postmenopausal RLS.
Finally, a preliminary randomized trial [68] reported beneficial
effects of an 8-week gentle yoga program in 20 postmenopausal women
as well as pilot study in 13 women [69]. Further data are awaited.
4. Summary and recommendations
• Menopausal sleep disorders have a wide variety of manifestations,
including not only insomnia but also breathing and movement dis-
orders. VMS have a large effect on postmenopausal women's sleep,
mood, and quality of life. Treatment needs to be individualized,
taking into account comorbidities and preferences.
• Insomnia per se best responds to CBT-I, MHT, and escitalopram.
New drugs with different therapeutic targets are in development.
• Melatonin may stabilize circadian rhythm while helping insomnia
symptoms as well as VMS.
• CPAP and MADs decrease the hypertension burden of OSA, but
without a major impact on sleep quality and mortality risk.
• The data regarding MHT on RLS and PLMs are conflicting. MHT may
have a preventive role rather than being a treatment option.
• There is a need for adequately powered randomized controlled trials
as well as cohort studies to better understand the impact of meno-
pausal sleep disorders and increase the evidence-base of therapeutic
strategies.
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